ClinicalTrials.gg
RecruitingNCT04012671Updated Mar 22, 2021

A Registered Cohort Study on Duchenne Muscular Dystrophy

An observational study in Duchenne Muscular Dystrophy, sponsored by Ning Wang, MD., PhD.. Recruiting at 1 site in China. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2021-03-22.

Sponsored by Ning Wang, MD., PhD. · Observational

How we know

From the registry’s dates

  • Started Jul 2019; still recruiting 7 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Muscular Dystrophy, Duchenne with a site in China — 5 open to participants now, 10 under way, 1 of them phase 3. Muscular Dystrophy, Duchenne · China.

Started
2019
with 2 others
Observational
2 of 19
2 open now
Registered
6th of 19
by date
Lead sponsor
1 of 19
Ning Wang, MD., PhD.

Among the 19 studies in Muscular Dystrophy, Duchenne with a site in China, this one is one of 3 that started in 2019, is one of 2 observational ones, and was the 6th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

5 of the 19 studies in Muscular Dystrophy, Duchenne with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Muscular Dystrophy, Duchenne with a site in China, or all of them as a file.
02

Study summary

Dystrophinopathy is a term of X-linked recessive genetic disease, including Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and the X-linked dilated cardiomyopathy. The aim of this study is to determine the clinical spectrum and natural progression of dystrophinopathy in a prospective multicenter natural history study, to assess the clinical, genetic of patients with dystrophinopathy to optimize clinical management.

03

Conditions studied

  • Duchenne Muscular Dystrophy
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who are diagnosed as Duchenne Muscular Dystrophy in the hosipital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Beyond 2 years old
  • Diagnosis with Duchenne Muscular Dystrophy, and female carriers, genotypically confirmed
  • Diagnosis should be supported by muscle , if no genetic confirmation.

Exclusion criteria

Exclusion Criteria:

  • Presence of other illness
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Age at death

    the time when patient die

    Time frame: 20 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2019 (actual). Primary completion is estimated for Dec 2039, 245 months after the start.

Of 52 non-industry observational studies under Muscular Dystrophy, Duchenne, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 120. This study's planned 245 months is above that.

Counting every sponsor, half of 63 studies reached it within 40 months; a quarter within 12 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2019
First posted
Jul 9, 2019
StartActual
Jul 1, 2019
Primary completionEst.
Dec 31, 2039
CompletionEst.
Dec 31, 2049
Last update
Mar 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04012671
Lead sponsor
Ning Wang, MD., PhD.
Responsible party
Ning Wang, MD., PhD. (Professor, First Affiliated Hospital of Fujian Medical University) — Sponsor-investigator
First posted
Jul 9, 2019
Start date
Jul 1, 2019
Primary completion
Dec 31, 2039 (estimated)
Completion
Dec 31, 2049 (estimated)
Last update
Mar 22, 2021

Study contacts

Ning Wang, MD, PhD
Contact
ningwang@fjmu.edu.cn
13805015340 ext. 13805015340
Ming Jin, MD
Contact
Safariday@live.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion